Citations

Mayo Clinic

Showing 10 of 108523 citations.

Robotic-Assisted Laparoscopic Surgery of Urachal Anomalies: A Single-Center Experience
Rivera, Marcelino , Granberg, Candace F. , Tollefson, Matthew K.

Journal of Laparoendoscopic & Advanced Surgical Techniques | April 8, 2015 | Volume: 25 | Issue: 4 | Pages: 291-294

10.1089/lap.2014.0551 | PMID 25853182 Get It

The Cup of Diogenes: A Fixed Anatomical Landmark for Carpal Tunnel Surgery
Wagner, Eric R. , Shin, Alexander Y. , Houdek, Matthew T. , Shin, Alexander Y , Wagner, Eric R

HAND | April 8, 2015 | Volume: 10 | Issue: 4 | Pages: 712-716

10.1007/s11552-015-9753-z | PMID 26568728 Get It

Purpose Carpal tunnel syndrome is a common entrapment neuropathy. When conservative management fails to relieve symptoms, carpal tunnel surgery is indicated. The surgical exposure for this procedure is commonly based on variable anatomic landmarks. The purpose of this study was to describe a fixed, easily referenced anatomical landmark for the distal extension of the transverse carpal ligament, the “Cup of Diogenes.” Materials and Methods Topographical landmarks including Kaplan cardinal line, palmaris tendon, and distal palmer crease were marked on six fresh frozen cadaveric wrist and hand specimens. The apex of the Cup of Diogenes is determined to be the confluence of the thenar and hypothenar musculature of the palm. Wrists were dissected and the distance between these landmarks and the superficial palmar arch, median nerve, transverse carpal ligament, and ulnar nerve were measured. Results In all specimens, the ulnar nerve was ulnar to this the apex of the Cup of Diogenes, while the median nerve was radial. The apex was proximal in all specimens to the superficial palmar arch. The apex marked the distal extent of the transverse carpal ligament in all specimens. Discussion Based on our results, we feel the apex of the Cup of Diogenes is a consistent, fixed anatomical marker for the distal extent of the transverse carpal ligament, marking a safe zone in the palm for surgical planning of incisions. Level of Evidence Level V - Therapeutic
ASXL1 mutations are frequent and prognostically detrimental in CSF3R‐mutated chronic neutrophilic leukemia
Elliott, Michelle A. , Pardanani, Animesh , Hanson, Curtis A. , Finke, Christy M. , Belachew, Alem A. , Tefferi, Ayalew , Lasho, Terra L.

American Journal of Hematology | April 8, 2015 | Volume: 90 | Issue: 7 | Pages: 653-656

10.1002/ajh.24031 | PMID 25850813 Get It

Colony stimulating factor 3 receptor gene (CSF3R) mutations have recently been associated with chronic neutrophilic leukemia (CNL). Fourteen patients with CSF3R‐mutated CNL (median age 67 years; 57% males) were screened for additional mutations; 8 (57%) and 5 (38%) harbored an ASXL1 and/or SETBP1 mutation (two patients expressed both), respectively. Two patients developed blastic transformation, both SETBP1‐mutated and ASXL1‐unmutated, whereas two other cases evolved into chronic myelomonocytic leukemia (CMML), both ASXL1‐mutated and SETBP1‐unmutated. Median survival was 23.2 months (10 deaths documented). On multivariable analysis mutated ASXL1 (P = 0.009; HR 19.6, 95% CI 2.1–184.1) and thrombocytopenia (P = 0.005; HR 28.8, 95% CI 2.8–298.2) were independently predictive of shortened survival. This study provides information on the natural history of CSF3R‐mutated CNL and identifies mutant ASXL1 and thrombocytopenia as risk factors for survival. The study also suggests pathogenetic roles for SETBP1 and ASXL1 mutations in disease evolution into blast phase disease and CMML, respectively. Am. J. Hematol. 90:653–656, 2015. © 2015 Wiley Periodicals, Inc.
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States
Nabhan, Chadi , Byrtek, Michelle, Rai, Ashish , Dawson, Keith, Zhou, Xiaolei , Link, Brian K. , Friedberg, Jonathan W. , Flowers, Christopher R. , Zelenetz, Andrew D. , Maurer, Matthew J. , Cerhan, James R. , Link, Brian K

British Journal of Haematology | April 8, 2015 | Volume: 170 | Issue: 1 | Pages: 85-95

10.1111/bjh.13399 | PMID 25851937 Get It

SummaryData from the National LymphoCare Study (a prospective, multicentre registry that enrolled follicular lymphoma (FL) patients from 2004 to 2007) were used to determine disease characteristics, treatment patterns, outcomes and prognosis for elderly FL (eFL) patients. Of 2650 FL patients, 209 (8%) were aged >80 years; these eFL patients more commonly had grade 3 disease, less frequently received chemoimmunotherapy and anthracyclines, and had lower response rates when compared to younger patients. With a median follow‐up of 6.9 years, 5‐year overall survival (OS) for eFL patients was 59%; 38% of deaths were lymphoma‐related. No treatment produced superior OS among eFL patients. In multivariate Cox models, anaemia, B‐symptoms and male sex predicted worse OS (P < 0·01); a prognostic index of these factors (0, 1 or ≥2 present) predicted OS [hazard ratio (95% CI): ≥2 vs. 0, 4·72 (2·38–9·33); 1 vs. 0, 2·63 (1·39–4·98)], with a higher concordance index (0·63) versus the Follicular Lymphoma International Prognostic Index (0·55). The index was validated in an independent cohort. In the largest prospective US‐based eFL cohort, no optimal therapy was identified and nearly 40% of deaths were lymphoma‐related, representing baseline outcomes in the modern era.
Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans
Lalia, Antigoni Z., Jensen, Michael D. , Hames, Kazanna C. , Port, John D. , Lanza, Ian R. , Johnson, Matthew L. , Lanza, Ian R , Port, John D

Diabetes Care | April 8, 2015 | Volume: 38 | Issue: 7 | Pages: 1228-1237

10.2337/dc14-3101 | PMID 25852206 Get It

OBJECTIVE Dietary n-3 polyunsaturated fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), prevent insulin resistance and stimulate mitochondrial biogenesis in rodents, but the findings of translational studies in humans are thus far ambiguous. The aim of this study was to evaluate the influence of EPA and DHA on insulin sensitivity, insulin secretion, and muscle mitochondrial function in insulin-resistant, nondiabetic humans using a robust study design and gold-standard measurements. RESEARCH DESIGN AND METHODS Thirty-one insulin-resistant adults received 3.9 g/day EPA+DHA or placebo for 6 months in a randomized double-blind study. Hyperinsulinemic-euglycemic clamp with somatostatin was used to assess hepatic and peripheral insulin sensitivity. Postprandial glucose disposal and insulin secretion were measured after a meal. Measurements were performed at baseline and after 6 months of treatment. Abdominal fat distribution was evaluated by MRI. Muscle oxidative capacity was measured in isolated mitochondria using high-resolution respirometry and noninvasively by magnetic resonance spectroscopy. RESULTS Compared with placebo, EPA+DHA did not alter peripheral insulin sensitivity, postprandial glucose disposal, or insulin secretion. Hepatic insulin sensitivity, determined from the suppression of endogenous glucose production by insulin, exhibited a small but significant improvement with EPA+DHA compared with placebo. Muscle mitochondrial function was unchanged by EPA+DHA or placebo. CONCLUSIONS This study demonstrates that dietary EPA+DHA does not improve peripheral glucose disposal, insulin secretion, or skeletal muscle mitochondrial function in insulin-resistant nondiabetic humans. There was a modest improvement in hepatic insulin sensitivity with EPA+DHA, but this was not associated with any improvements in clinically meaningful outcomes.
Early Career Experience of Pediatric Orthopaedic Fellows: What to Expect and Need for Their Services
Glotzbecker, Michael P. , Larson, A. Noelle , Hydorn, Christopher R., Sawyer, Jeffery R., Shore, Benjamin J. , Fletcher, Nicholas D , Larson, A Noelle

Journal of Pediatric Orthopaedics | April 8, 2015 | Volume: 36 | Issue: 4 | Pages: 429-432

10.1097/bpo.0000000000000452 | PMID 25851674 Get It

Introduction: A dramatic increase in the number of pediatric orthopaedic fellows being trained has led to concerns that there may be an oversupply of pediatric orthopaedists. The purpose of this study was to determine whether this perception is accurate and whether the practice expectations of recent pediatric fellowship graduates are being met by surveying recent pediatric fellowship graduates about their early practice experiences. Methods: A 36-question survey approved by the Pediatric Orthopaedic Society of North America (POSNA) leadership was electronically distributed to 120 recent graduates of pediatric orthopaedic fellowships; 81 responses were ultimately obtained (67.5% response rate). Results: Almost all (91%) of the respondents were very or extremely satisfied with their fellowship experience. Half of the respondents had at least 1 job offer before they entered their fellowships. After completion of fellowships, 35% received 1 job offer and 62.5% received ≥2 job offers; only 2.5% did not receive a job offer. Most reported a practice consisting almost entirely of pediatric orthopaedics, and 93.5% thought this was in line with their expectations; 87% indicated satisfaction with their current volume of pediatric orthopaedics, and 85% with the complexity of their pediatric orthopaedic cases. Despite the high employment percentages and satisfaction with practice profiles, nearly a third (28%) of respondents replied that too many pediatric orthopaedists are being trained. Conclusions: Positive messages from this survey include the satisfaction of graduates with their fellowship training, the high percentage of graduates who readily found employment, and the satisfaction of graduates with their current practice environments; this indicates that the pediatric orthopaedic job environment is not completely saturated and there are continued opportunities for graduating pediatric fellows despite the increased number of fellows being trained. Although not determined by this study, it may be that the stable demand for pediatric orthopaedic services is being driven by the expansion of the scope of practice as well as subspecialization within the practice of pediatric orthopaedics.
Spontaneous Hyphema after Cardiac Surgery
Barbara, David W. , Pulido, Juan N. , Leavitt, Jacqueline A., Gillespie, Shane

Anesthesiology | April 8, 2015 | Volume: 123 | Issue: 5 | Pages: 1186-1186

10.1097/aln.0000000000000676 | PMID 25851094 Get It

Effect of Left Ventricular Ejection Fraction on Postoperative Outcome in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement
Dahl, Jordi S. , Eleid, Mackram F. , Suri, Rakesh M. , Schaff, Hartzell V. , Pellikka, Patricia A. , Michelena, Héctor I. , Scott, Christopher G. , Pellikka, Patricia A , Dahl, Jordi S , Schaff, Hartzell

Circulation: Cardiovascular Imaging | April 8, 2015 | Volume: 8 | Issue: 4 | Pages: No page available

10.1161/circimaging.114.002917 | PMID 25852129 Get It

Background— In asymptomatic patients with severe aortic stenosis, guidelines recommend left ventricular ejection fraction (LVEF) of <50% as the threshold for referral for aortic valve replacement. We investigated the importance of LVEF on long-term outcome after aortic valve replacement in symptomatic and asymptomatic patients with severe aortic stenosis. Methods and Results— We retrospectively identified 2017 patients with severe aortic stenosis (aortic valve area<1 cm 2 , mean gradient≥40 mm Hg, or indexed aortic valve area<0.6 cm 2 /m 2 ) who underwent surgical aortic valve replacement from January 1995 to June 2009. Patients were divided into 4 groups depending on preoperative LVEF (<50% in 300 [15%] patients, 50%–59% in 331 [17%], 60%–69% in 908 [45%], and ≥70% in 478 [24%]). During follow-up of 5.3±4.4 years, 1056 (52%) patients died. A decrease in mortality was observed with increasing LVEF, P <0.0001; 5-year mortality estimates (95% confidence interval) were 0.41 (0.35–0.47), LVEF<50%; 0.35 (0.29–0.41), LVEF 50% to 59%; 0.26 (0.23–0.29), LVEF 60% to 69%; and 0.22 (0.18–0.26), LVEF≥70%. Compared with patients with LVEF≥60%, patients with LVEF 50% to 59% had increased mortality (hazard ratio [HR], 1.58; P <0.001), with similar risk increase in both symptomatic (HR, 1.56; P <0.001) and asymptomatic patients (HR, 1.58; P =0.006). Correcting for risk factors, LV mass index, aortic valve area, and stroke volume index, LVEF was independently predictive of mortality (HR, 0.88 per 10%; P <0.001). When this analysis was repeated in the subset of 1333 patients without history of coronary artery disease, LVEF remained associated with mortality (HR, 0.90 per 10%; P =0.009). Conclusions— LVEF is a powerful predictor of outcome in patients with severe aortic stenosis undergoing aortic valve replacement, independent of the presence of valve-related symptoms.
Effective Targeting of Estrogen Receptor–Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101
Borgés, Sahra, Perez, Edith A. , Thompson, E. Aubrey , Geiger, Xochiquetzal J., Störz, Peter , Radisky, Derek C.

Molecular Cancer Therapeutics | April 8, 2015 | Volume: 14 | Issue: 6 | Pages: 1306-1316

10.1158/1535-7163.mct-14-0945 | PMID 25852060 Get It

Abstract Invasive ductal carcinomas (IDC) of the breast are associated with altered expression of hormone receptors (HR), amplification or overexpression of HER2, or a triple-negative phenotype. The most aggressive cases of IDC are characterized by a high proliferation rate, a great propensity to metastasize, and their ability to resist to standard chemotherapy, hormone therapy, or HER2-targeted therapy. Using progression tissue microarrays, we here demonstrate that the serine/threonine kinase protein kinase D3 (PKD3) is highly upregulated in estrogen receptor (ER)–negative (ER−) tumors. We identify direct binding of the ER to the PRKD3 gene promoter as a mechanism of inhibition of PKD3 expression. Loss of ER results in upregulation of PKD3, leading to all hallmarks of aggressive IDC, including increased cell proliferation, migration, and invasion. This identifies ER− breast cancers as ideal for treatment with the PKD inhibitor CRT0066101. We show that similar to a knockdown of PKD3, treatment with this inhibitor targets all tumorigenic processes in vitro and decreases growth of primary tumors and metastasis in vivo. Our data strongly support the development of PKD inhibitors for clinical use for ER− breast cancers, including the triple-negative phenotype. Mol Cancer Ther; 14(6); 1306–16. ©2015 AACR.
Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke
Fugate, Jennifer E. , Rabinstein, Alejandro A.

The Neurohospitalist | April 8, 2015 | Volume: 5 | Issue: 3 | Pages: 110-121

10.1177/1941874415578532 | PMID 26288669 Get It

Most of the contraindications to the administration of intravenous (IV) recombinant tissue plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These were derived from expert consensus for the National Institute of Neurological Disorders and Stroke (NINDS) trial. Despite the fact that the safety and efficacy of IV rtPA has been repeatedly confirmed in large international observational studies over the past 20 years, most patients with acute ischemic stroke disappointingly still do not receive thrombolytic treatment. Some of the original exclusion criteria have proven to be unnecessarily restrictive in real-world clinical practice. It has been suggested that application of relaxed exclusion criteria might increase the IV thrombolysis rate up to 20% with comparable outcomes to thrombolysis with more conventional criteria. We review the absolute and relative contraindications to IV rtPA for acute ischemic stroke, discussing the underlying rationale and evidence supporting these exclusion criteria.